Neoadjuvant Cemiplimab in Stage I-II Merkel Cell Carcinoma: Safety and Biomarker Analysis
Status:
Recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to determine if Cemiplimab-rwlc (called
Cemiplimab in this document) given prior to tumor resection surgery is safe and effective in
treating Merkel Cell Carcinoma.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute